NCT04801758View on ClinicalTrials.gov

Analytical Treatment Interruption (ATI) to Assess the Immune System's Ability to Control HIV in Participants Who Became HIV-infected During the HVTN 704/HPTN 085 AMP Study

NACompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

August 22, 2022

Primary Completion Date

July 22, 2024

Study Completion Date

July 22, 2024

Conditions
HIV Infection
Interventions
OTHER

Analytical Treatment Interruption

"Participants will stop taking their HIV medication and will stay off HIV medication unless and until the HIV levels in their blood show that their immune system is not controlling their HIV or they meet other ART re-start criteria as noted in section Detailed Description."

Trial Locations (6)

1

Asociacion Civil Selva Amazonica (ACSA), Iquitos CRS, Iquitos

15001

Via Libra CRS, Lima

15081

Centro de Investigaciones Tecnológicas, Biomédicas y Medioambientales, San Marcos CRS, Callao

21040-360

Instituto de Pesquisa Clinica Evandro Chagas (IPEC), FIOCRUZ, Rio de Janeiro

04-15063

Asociacion Civil Impacta Salud y Educacion, Barranco CRS, Lima

32-15088

San Miguel CRS, Lima

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

collaborator

HIV Prevention Trials Network

NETWORK

collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

HIV Vaccine Trials Network

NETWORK